Human Trials

Zynerba halts development of THC prodrug ZYN001

A failure in a phase 1 clinical program has forced Zynerba Pharmaceuticals to stop development of ZYN001, its pro-drug of tetrahydrocannabinol (THC) intended for the treatment of neuropsychiatric disorders including Tourette Syndrome.

Anavex gets approval to begin phase 2b/3 trial of Alzheimer’s disease treatment

Anavex Life Sciences has secured approval from the Australian Human Research Ethics Committee to begin its phase 2b/3 trial of Anavex 2-73 to treat early Alzheimer’s disease.

Lynparza delays disease progression in phase III trial for ovarian cancer

AstraZeneca and Merck have announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets.

Arcus, Infinity to evaluate two triple combination therapies in selected tumor types

Arcus Biosciences and Infinity Pharmaceuticals have entered into a clinical collaboration to evaluate two triple combination therapies in certain tumor types which typically show minimal response to checkpoint inhibition monotherapy.

Synairgen reports positive safety data for SNG001 in phase 2 COPD trial

Synairgen said that its antiviral therapy SNG001 has so far registered positive safety data in an ongoing phase 2 trial in patients with chronic obstructive pulmonary disease (COPD).

New drug cuts hearing loss in children by 50% after cancer treatment

A clinical trial, funded by Cancer Research UK, has shown that administering sodium thiosulphate (STS) after chemotherapy ‘cisplatin’ for the treatment of childhood liver cancer hepatoblastoma reduces hearing loss in children by almost 50%.

Novo Nordisk’s semaglutide succeeds in two phase 3a type 2 diabetes trials

Novo Nordisk said that oral semaglutide succeeded in two phase 3a trials by registering statistically significantly greater reductions in HbA1c and weight in adults with type 2 diabetes.

Can-Fite delays phase 2 trial of liver cancer drug Namodenoson

Israeli biotechnology company Can-Fite BioPharma revealed that the results of its phase 2 trial of its liver cancer drug Namodenoson (CF102) will be delayed longer than originally estimated.

BMS’ elotuzumab / pomalidomide improves progression-free survival in cancer trial

Bristol-Myers Squibb (BMS) has announced that the ELOQUENT-3 trial, an international Phase 2 study evaluating the addition of Empliciti (elotuzumab) to pomalidomide and low-dose dexamethasone (EPd) in patients with relapsed/refractory multiple myeloma (RRMM), achieved its primary endpoint.